W STRATEGIES, LLC for ALEXION PHARMACEUTICALS
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
H.R. 1314: Trade Preferences Extension Act as it relates to access to orphan drug therapies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Medicare/Medicaid MMM
Educated staff about access to therapies for rare diseases. Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Copyright/Patent/Trademark CPT
H.R. 9: Innovation Act, including proposed changes to the Inter Partes Review (IPR) process at the Patent and Trademark Office (PTO). S. 1137: PATENT Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Health Issues HCR
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars. H.R. 6: 21st Century Cures Act. Education about the value of innovative new medicines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.